An official website of the United States government
Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
On June 27, 2024, the CDC Director adopted the ACIP’s recommendations for use of 2024–2025 COVID-19 vaccines in people ages 6 months and older as approved or authorized by FDA. The 2024–2025 vaccines are expected to be available in fall 2024. This page will be updated at that time to align with the new recommendations. Learn more.
Some 2023-2024 COVID-19 vaccines will expire in summer 2024
Expiration dates vary by manufacturer and vaccine. Always check the expiration date or beyond-use date/time to ensure it has not passed. Never use expired vaccine or diluent.
See the Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States for information on interchangeability of COVID-19 vaccines.
Summary of recent changes (last updated April 4, 2024):
- New guidance on COVID-19 vaccination and pemivibart (Pemgarda™), a monoclonal antibody authorized for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and meet the FDA-authorized conditions for use.
Reference Materials
- COVID-19 Vaccine Product Information (Updated 3/19/2024)
- Interim 2023–2024 COVID-19 Immunization Schedule for Persons 6 Months of Age and Older (Updated 4/03/2024)
- FAQs for the Interim Clinical Considerations (Updated 4/5/2024)
- COVID-19 Vaccination Recommendations Infographic (Updated 3/5/2024)
- COVID-19 Vaccination Recommendations Infographic (Immunocompromised) (Updated 10/13/2023)
Get Email Updates
Receive email updates about this page.
Special Situations and Populations